堃博醫療-B(02216.HK)擬全球發售8935.5萬股 引入瑞銀及雪湖資本等多家基石
格隆匯9月13日丨堃博醫療-B(02216.HK)發佈公告，公司擬全球發售8935.5萬股股份，其中香港發售股份893.55萬股，國際發售股份8041.95萬股，另有15%超額配股權；2021年9月13日至9月16日招股，預期定價日爲9月16日；發售價每股發售股份17.20港元-18.70港元，每手買賣單位500股，入場費約9444港元；高盛及海通國際爲聯席保薦人；預期股份將於2021年9月24日於聯交所主板掛牌上市。
集團是一家專注於介入呼吸病學產品開發的醫療器械公司。成立於2012年，集團是介入呼吸病學領域的開拓者，在中國和全球範圍內提供創新型肺部疾病解決方案。集團利用專有的全肺抵達導航技術，開發了一款包括導航、診療的綜合介入呼吸病學平臺，通過提高肺癌及慢性阻塞性肺病的診療效果解決了現有診療模式的痛點以及大量未得到滿足的肺病醫療需求。截至最後實際可行日期，集團有17種產品及處於不同開發階段的主要候選產品。集團的核心產品是InterVapor系統及RF發生器+RF消融導管。根據弗若斯特沙利文的資料， InterVapor系統是世界上第一個，也是唯一一個用於治療慢性阻塞性肺病及肺癌等肺病的熱蒸汽能量消融系統。RF-II是一種與一次性肺射頻消融導管結合使用及唯一專門針對肺癌的射頻消融系統。截至最後實際可行日期，集團分別擁有132項和60項有關InterVapor和RF-II的專利和專利申請。
集團已與基石投資者訂立基石投資協議，據此，基石投資者已同意按發售價認購以總金額9100萬美元(或約7.07億港元)可購買的若幹數目發售股份。假設發售價爲17.95港元(即發售價範圍中位數)，基石投資者將予認購的發售股份總數將爲3939.7萬股，相當於全球發售項下發售股份約44.1%及緊隨全球發售完成後已發行股本總額約7.5%(假設超額配售權未獲行使)。基石投資者包括UBS Asset Management (Singapore) Ltd. 、 Lake Bleu Prime、雪湖資本、CEPHEI、Summer Healthcare Fund、Springhill Master Fund Limited、Artisan China Post-Venture Master Fund LP、Valliance Fund、Emerging Markets Healthcare Partners LLC、及Worldwide Healthcare Partners LLC。
假設超額配售權未獲行使及假設發售價爲每股17.95港元(即發售價範圍中位數)，集團估計將收取的所得款項淨額約爲14.881億港元。集團擬將全球發售所得款項淨額29.0%用於爲InterVapor正在進行及計劃的研發和商業上市提供資金；21.0%將用於爲RF-II正在進行及計劃的研發和商業上市提供資金；18.5%分配予集團的其他產品及候選產品；9.2%將用於爲繼續擴大集團生產廠房的生產線提供資金；13.2%將用於爲通過潛在收購持續擴大產品組合提供資金；9.2%將用於營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
